Dr. Aditya Bardia, a board-certified medical oncologist, is an Attending Physician at Massachusetts General Hospital (MGH), Associate Professor, Harvard Medical School, Boston. As the Director of Breast Cancer Research Program at MGH, Dr. Bardia is interested in advancing research to improve the outcomes with breast cancer. Dr. Bardia has led the clinical development of antibody drug conjugate (ADC), sacituzumab govitecan, the first ADC approved for patients with metastatic triple negative breast cancer. Dr. Bardia has received several research awards including outstanding award for research excellence at Mayo Clinic, Young Investigator Award from ASCO, and Douglas Family Foundation prize for excellence in oncology research at MGH. Dr. Bardia is the editor of precision medicine clinic section of The Oncologist, co-leader of the Molecular and Precision (MAP) tumor board at MGH, and editorial board member of ASCO molecular oncology tumor board.